Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma

por Chekol Abebe, Endeshaw, Yibeltal Shiferaw, Mestet, Tadele Admasu, Fitalew, Asmamaw Dejenie, Tadesse
Publicado 2022